Novartis (NVS) said Friday the World Health Organization prequalified its antimalarial medication, which allows for widespread access to a treatment developed for newborns and young infants weighing two to five kilograms.

WHO runs the prequalification process to assess the quality, safety, and efficacy of treatments, according to Novartis. United Nations and other procurement agencies use the prequalification outputs, including lists of prequalified products, to inform funding and purchasing decisions for the public sector.

Novartis will make the treatment available on a largely not-for-profit basis in malaria-endemic regions, it said.

Coartem, also known as riamet baby in some countries, was developed in collaboration with Medicines for Malaria Venture, the Swiss pharmaceutical company said.